Literature DB >> 29706522

The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer.

C M Nagle1, E J Crosbie2, A Brand3, A Obermair4, M K Oehler5, M Quinn6, Y Leung7, A B Spurdle8, P M Webb9.   

Abstract

OBJECTIVE: Although endometrial cancer (EC) is associated with relatively good survival rates overall, women diagnosed with high-risk subtypes have poor outcomes. We examined the relationship between lifestyle factors and subsequent all-cause, cancer-specific and non-cancer related survival.
METHODS: In a cohort of 1359 Australian women diagnosed with incident EC between 2005 and 2007 pre-diagnostic information was collected by interview at recruitment. Clinical and survival information was abstracted from women's medical records, supplemented by linkage to the Australian National Death Index. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause and cause-specific survival (EC death vs. non-EC death) associated with each exposure, overall and by risk group (low-grade endometrioid vs. high-grade endometrioid and non-endometrioid).
RESULTS: After a median follow-up of 7.1 years, 179 (13%) women had died, with 123 (69%) deaths from EC. As expected, elevated body mass index (BMI), diabetes and the presence of other co-morbidities were associated with a significantly increased risk of all-cause and non-cancer related death. Women with diabetes had higher cancer-specific mortality rates (HR 2.09, 95% CI 1.31-3.35), particularly those who had were not obese (HR 4.13, 95% CI 2.20-7.76). The presence of ≥2 other co-morbidities (excluding diabetes) was also associated with increased risk of cancer-specific mortality (HR 3.09, 95% CI 1.21-7.89). The patterns were generally similar for women with low-grade and high-grade endometrioid/non-endometrioid EC.
CONCLUSION: Our findings demonstrate the importance of diabetes, other co-morbidities and obesity as negative predictors of mortality among women with EC but that the risks differ for cancer-specific and non-cancer related mortality.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Body mass index; Cause-specific survival; Co-morbidities; Diabetes; Endometrial cancer; Survival

Mesh:

Year:  2018        PMID: 29706522     DOI: 10.1016/j.ygyno.2018.04.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

1.  Lipid-lowering medication use and cancer-specific survival among endometrial or lung cancer patients: an Australian nationwide cohort study.

Authors:  Jia-Li Feng; Xiwen Qin
Journal:  Eur J Clin Pharmacol       Date:  2020-10-08       Impact factor: 2.953

2.  Prospective Cohort Study of Pre- and Postdiagnosis Obesity and Endometrial Cancer Survival.

Authors:  Renée L Kokts-Porietis; Jessica McNeil; Andria R Morielli; Linda S Cook; Kerry S Courneya; Christine M Friedenreich
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 11.816

3.  The Influence of the Metabolic Syndrome on Early Postoperative Outcomes of Patients With Advanced-stage Endometrial Cancer.

Authors:  Nicolae Bacalbasa; Camelia Diaconu; Laura Iliescu; Cornel Savu; Carmen Savu; Cristian Balalau; Mihai Dimitriu; Alexandru Filipescu; Ovidiu Gabriel Bratu; Adrian Neacsu; Dragos Cretoiu; Ioana Halmaciu; Irina Balescu
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

4.  Long-term diabetes risk among endometrial cancer survivors in a population-based cohort study.

Authors:  Seungmin Kim; Jihye Park; Yuji Chen; Kerry Rowe; John Snyder; Alison Fraser; Ken Smith; Vikrant G Deshmukh; Michael Newman; Kimberley Herget; Christina A Porucznik; Dominik Ose; Mary Playdon; David Gaffney; Mia Hashibe
Journal:  Gynecol Oncol       Date:  2019-12-12       Impact factor: 5.482

5.  No Association Between Statin Use and the Prognosis of Endometrial Cancer in Women With Type 2 Diabetes.

Authors:  Elina Urpilainen; Anne Ahtikoski; Reetta Arima; Ulla Puistola; Peeter Karihtala
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

6.  Impact of socio-economic deprivation on endometrial cancer survival in the North West of England: a prospective database analysis.

Authors:  K Njoku; C E Barr; L Hotchkies; N Quille; Y L Wan; E J Crosbie
Journal:  BJOG       Date:  2021-01-11       Impact factor: 6.531

7.  Fertility-sparing treatment in early endometrial cancer: current state and future strategies.

Authors:  Andreas Obermair; Eva Baxter; Donal J Brennan; Jessica N McAlpine; Jennifer J Muellerer; Frédéric Amant; Mignon D J M van Gent; Robert L Coleman; Shannon N Westin; Melinda S Yates; Camilla Krakstad; Monika Janda
Journal:  Obstet Gynecol Sci       Date:  2020-07-08

8.  Patients with endometrial cancer continue to lack understanding of their risks for cancer.

Authors:  Subhjit Sekhon; L Stewart Massad; Andrea R Hagemann; Rebecca Dick; Andrea Leon; Abigail S Zamorano; Premal H Thaker; Carolyn K McCourt; David G Mutch; Matthew A Powell; Lindsay M Kuroki
Journal:  Gynecol Oncol Rep       Date:  2019-08-10

Review 9.  The Role of Metabolic Syndrome in Endometrial Cancer: A Review.

Authors:  Xiao Yang; Jianliu Wang
Journal:  Front Oncol       Date:  2019-08-08       Impact factor: 6.244

10.  CircRNA WHSC1 targets the miR-646/NPM1 pathway to promote the development of endometrial cancer.

Authors:  Yao Liu; Shuo Chen; Zhi-Hong Zong; Xue Guan; Yang Zhao
Journal:  J Cell Mol Med       Date:  2020-05-07       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.